ApolloBio announced positive topline results from its phase 3 trial of VGX-3100, a DNA immunotherapy developed by INOVIO Pharmaceuticals (NASDAQ ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE